Literature DB >> 10369942

Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test.

S Leide-Svegborn1, K Stenström, M Olofsson, S Mattsson, L E Nilsson, B Nosslin, K Pau, L Johansson, B Erlandsson, R Hellborg, G Skog.   

Abstract

The long-term biokinetics and dosimetry of carbon-14 were studied in nine adults and eight children undergoing carbon-14 urea breath test for Helicobacter pylori (HP) infection. The elimination of 14C via exhaled air and urine was measured with the liquid scintillation counting technique and with accelerator mass spectrometry. After the subjects had been given 110 kBq 14C-urea (children: 55 kBq) orally, samples of exhaled air were taken up to 180 days after administration and samples of urine were collected up to 40 days. Sixteen of the subjects were found to be HP-negative. In these subjects a total of 91.1%+/-3.9% (mean of adults and children +/- standard error of the mean) of the administered 14C activity was recovered. The majority of the administered activity, 88.3%+/-6.2% in adults and 87.7%+/-5.0% in children, was excreted via the urine within 72 h after administration. A smaller fraction was exhaled. In adults 4.6%+/-0.6% of the activity was exhaled within 20 days and in children 2.6%+/-0.3%. Uncertainties in the biokinetic results are mainly due to assumptions concerning endogenous CO2 production and urinary excretion rate and are estimated to be less than 30%. The absorbed dose to various organs and the effective dose were calculated using the ICRP model for urea and CO2. The urinary bladder received the highest absorbed dose: in adults, 0.15+/-0.01 mGy/MBq and in children of various ages (7-14 years), 0.14-0.36 mGy/MBq. The findings indicate that an investigation with 14C-urea gives an effective dose to adults of 2.1+/-0.1 microSv (for 110 kBq) and to children of 0.9-2.5 microSv (for 55 kBq). From a radiation protection point of view, there is thus no reason for restrictions on even repeated screening investigations with 14C-urea in whole families, including children.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369942     DOI: 10.1007/s002590050424

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  12 in total

Review 1.  Accelerator mass spectrometry-enabled studies: current status and future prospects.

Authors:  Ali Arjomand
Journal:  Bioanalysis       Date:  2010-03       Impact factor: 2.681

Review 2.  Safety of 14C-UBT for diagnosis of Helicobacter pylori infection in pregnancy.

Authors:  Yedidia Bentur; Doreen Matsui; Gideon Koren
Journal:  Can Fam Physician       Date:  2009-05       Impact factor: 3.275

Review 3.  Quantifying exploratory low dose compounds in humans with AMS.

Authors:  Stephen R Dueker; Le T Vuong; Peter N Lohstroh; Jason A Giacomo; John S Vogel
Journal:  Adv Drug Deliv Rev       Date:  2010-10-31       Impact factor: 15.470

Review 4.  Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis.

Authors:  Mazen Ferwana; Imad Abdulmajeed; Ali Alhajiahmed; Wedad Madani; Belal Firwana; Rim Hasan; Osama Altayar; Paul J Limburg; Mohammad Hassan Murad; Bandar Knawy
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

Review 5.  Diagnostic accuracy of the 14C-urea breath test in Helicobacter pylori infections: a meta-analysis.

Authors:  Qiaohui Zhou; Ling Li; Yaowei Ai; Zhihong Pan; Mingwen Guo; Jingbo Han
Journal:  Wien Klin Wochenschr       Date:  2016-11-15       Impact factor: 1.704

6.  Validity and cost comparison of 14carbon urea breath test for diagnosis of H Pylori in dyspeptic patients.

Authors:  Shahid Rasool; Shahab Abid; Wasim Jafri
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

7.  Unique features and risk factors of Helicobacter pylori infection at the main children's intermediate school in Rabigh, Saudi Arabia.

Authors:  Hamed Said Habib; Moustafa Abdelaal Hegazi; Hussam Aly Murad; Elamir Mahmoud Amir; Taher Fawzy Halawa; Basem Salama El-Deek
Journal:  Indian J Gastroenterol       Date:  2014-04-29

8.  Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption.

Authors:  Sigrid Leide-Svegborn; Lars Ahlgren; Lennart Johansson; Sören Mattsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-06       Impact factor: 9.236

9.  Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP.

Authors:  Yujin Kobayashi; Yoshihiro Hatta; Atsuko Hojo; Yoshimasa Kura; Yoshihito Uchino; Hiromichi Takahashi; Satomi Kiso; Yukio Hirabayashi; Mai Yagi; Hitomi Kodaira; Daisuke Kurita; Toshitake Tanaka; Katsuhiro Miura; Noriyoshi Iriyama; Sumiko Kobayashi; Umihiko Sawada; Masahiko Sugitani; Jin Takeuchi
Journal:  Exp Ther Med       Date:  2011-11-22       Impact factor: 2.447

10.  A new, practical, low-dose 14C-urea breath test for the diagnosis of Helicobacter pylori infection: clinical validation and comparison with the standard method.

Authors:  Emel Oztürk; Zeki Yeşilova; Seyfettin Ilgan; Nuri Arslan; Ahmet Erdil; Bülent Celasun; Mehmet Ozgüven; Kemal Dağalp; Onder Ovali; Hikmet Bayhan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-05       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.